The Role of Data Quality in Successful ePI Adoption

The pharmaceutical industry is moving towards digital ways of sharing medicine information with healthcare professionals, patients, and regulatory authorities. Electronic Product Information (ePI) supports this shift by making approved product information accessible in a structured digital format. However, successful ePI adoption involves more than converting existing documents into digital content. The accuracy, consistency, and completeness of pharmaceutical data play an equally important role.

When product information contains outdated details, inconsistent terminology, or missing fields, these issues can affect the reliability of digital content. Establishing strong data quality practices early helps pharmaceutical companies prepare for a smoother and more dependable ePI transition.

Why Data Quality Matters in ePI Adoption

Pharmaceutical product information draws on multiple sources, including product labels, regulatory submissions, safety documentation, and internal product databases. When these sources are not properly aligned, discrepancies can appear during digital transformation.

For example, differences in product names, dosage information, packaging details, or approved indications may create inconsistencies across documents and systems. These discrepancies can become more difficult to manage when information is transferred into structured digital formats.

Reliable data helps organizations maintain consistency across product information, reduce avoidable rework, and establish a more dependable foundation for future updates. It also supports better coordination between regulatory affairs, quality assurance, medical, and IT teams.

Common Data Quality Challenges in Pharmaceutical Organizations

Before introducing ePI processes, companies should understand the data issues that may affect their readiness. Some common challenges include:

Incomplete product records: Essential product details may be missing from source systems or stored in separate documents.
Inconsistent terminology: Different departments may use varying terms or naming conventions for the same product attribute.
Outdated information: Older versions of product information may remain in circulation across internal repositories.
Limited traceability: Teams may struggle to identify where a particular data element originated or when it was last updated.
Fragmented systems: Information spread across multiple platforms can make validation and synchronization more complicated.

Addressing these issues requires a structured approach to data governance rather than relying entirely on manual corrections during implementation.

Assessing Data Before Moving to Digital Formats

A practical starting point is to evaluate existing information against the needs of the intended ePI process. Organizations can use ePI readiness assessment services to examine their current data landscape, identify information gaps, and determine which records require remediation before conversion begins.

This assessment should consider data completeness, accuracy, consistency, ownership, and availability. Teams should also review how product information moves between source systems and downstream applications.

The findings can then be organized into a prioritized action plan. Critical data discrepancies can be addressed first, while longer-term improvements can be scheduled according to business impact, resource availability, and project timelines.

Establishing Strong Data Governance Practices

Data quality cannot be maintained through a one-time cleanup exercise. Pharmaceutical companies need clear processes for managing information throughout its lifecycle.

A strong governance framework should define who owns each data element, who can approve changes, and how updates are documented. Standardized naming conventions, validation rules, and review procedures can help reduce inconsistencies between departments.

Version control is particularly important because product information may change following regulatory updates or approved variations. Teams should be able to identify the current approved version, understand what has changed, and maintain an appropriate record of revisions.

Organizations should also establish regular data quality checks. These checks can help detect missing fields, duplicate records, inconsistent values, and other issues before they affect digital publishing workflows.

Integrating Data Quality into ePI Implementation

Data quality should remain a core consideration throughout the transition, not a separate activity completed before the project begins. Effective ePI implementation consulting can help organizations connect data preparation with content migration, system integration, validation, and publishing requirements.

A phased approach can make this process more manageable. Pharmaceutical companies may begin with a selected product or product group, validate the information structure, and review the results before expanding the process. Pilot activities can reveal data mapping problems, workflow gaps, and integration issues that might otherwise emerge later.

Where applicable, teams should also evaluate relevant structured data standards and technical specifications for their intended markets and publishing platforms. The objective is to ensure that information remains accurate and usable as it moves between systems.

Measuring and Maintaining Data Quality

Organizations need measurable indicators to understand whether their data quality practices are working. Useful measures may include the percentage of complete product records, the number of validation errors, the frequency of data discrepancies, and the time required to resolve identified issues.

These indicators should be reviewed regularly by the teams responsible for product information. Clear reporting helps stakeholders identify recurring problems, allocate resources, and improve processes over time.

Working with an experienced ePI consulting company can also help pharmaceutical organizations establish a practical improvement roadmap aligned with their existing systems, internal capabilities, and digital information goals.

Conclusion

Reliable data is one of the foundations of successful ePI adoption. By identifying data gaps early, defining ownership, standardizing information, and introducing ongoing validation, pharmaceutical companies can reduce avoidable errors and improve the consistency of digital product information.

For organizations preparing to modernize their product information processes, Deevita provides ePI Readiness and Strategy services to help assess current capabilities, identify gaps, and plan the next steps towards ePI adoption